相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mitochondria as playmakers of apoptosis, autophagy and senescence
Marianna Abate et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2020)
Breast cancer vaccines: Heeding the lessons of the past to guide a path forward
Cinzia Solinas et al.
CANCER TREATMENT REVIEWS (2020)
Triple negative breast cancer: A thorough review of biomarkers
Jesse Lopes da Silva et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)
Rationally Designed Ruthenium Complexes for Breast Cancer Therapy
Golara Golbaghi et al.
MOLECULES (2020)
Rhenium-Based Complexes and in Vivo Testing: A Brief History
Miles S. Capper et al.
CHEMBIOCHEM (2020)
Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer in Young Women: Emerging Data in the Era of Molecularly Targeted Agents
Ami N. Shah et al.
ONCOLOGIST (2020)
The Role of Beclin 1-Dependent Autophagy in Cancer
Silvia Vega-Rubin-de-Celis
BIOLOGY-BASEL (2020)
mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
Tian Tian et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma
Gabriella Misso et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
Recent advances in triple negative breast cancer: the immunotherapy era
Antonio Marra et al.
BMC MEDICINE (2019)
NAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry
Enzo Alessio et al.
MOLECULES (2019)
Therapeutic innovations in breast cancer
Fanny Le Du et al.
PRESSE MEDICALE (2019)
Lactate dehydrogenase A regulates autophagy and tamoxifen resistance in breast cancer
Chandan Kanta Das et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2019)
Chemoresistance mechanisms of breast cancer and their countermeasures
Xiwei Ji et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Autophagy as a molecular target for cancer treatment
Nur Mehpare Kocaturk et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Role of tumor and host autophagy in cancer metabolism
Laura Poillet-Perez et al.
GENES & DEVELOPMENT (2019)
Targeting BAX to drug death directly
Loren D. Walensky
NATURE CHEMICAL BIOLOGY (2019)
Exploring cellular uptake, accumulation and mechanism of action of a cationic Ru-based nanosystem in human preclinical models of breast cancer
Marialuisa Piccolo et al.
SCIENTIFIC REPORTS (2019)
Therapeutic landscape of metaplastic breast cancer
N. Tray et al.
CANCER TREATMENT REVIEWS (2019)
Development and future prospects of selective organometallic compounds as anticancer drug candidates exhibiting novel modes of action
Sabiha Parveen et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Cancer Metabolism and the Evasion of Apoptotic Cell Death
Aditi Sharma et al.
CANCERS (2019)
Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge
Milica Nedeljkovic et al.
CELLS (2019)
Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals
Malgorzata Szostakowska et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Transition Metal Complexes and Photodynamic Therapy from a Tumor-Centered Approach: Challenges, Opportunities, and Highlights from the Development of TLD1433
Susan Monro et al.
CHEMICAL REVIEWS (2019)
Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?
Reece G. Kenny et al.
CHEMICAL REVIEWS (2019)
Molecular mechanism of mammary gland involution: An update
Manoj Kumar Jena et al.
DEVELOPMENTAL BIOLOGY (2019)
Metal-based antitumor compounds: beyond cisplatin
Peter V. Simpson et al.
FUTURE MEDICINAL CHEMISTRY (2019)
Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer
Juliet Richman et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Alterations of the interactome of Bcl-2 proteins in breast cancer at the transcriptional, mutational and structural level
Simon Mathis Konig et al.
PLOS COMPUTATIONAL BIOLOGY (2019)
The role of autophagy in HER2-targeted therapy
Janser A. Felice et al.
SWISS MEDICAL WEEKLY (2019)
Designing Ruthenium Anticancer Drugs: What Have We Learnt from the Key Drug Candidates?
James P. C. Coverdale et al.
INORGANICS (2019)
First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro
Debora Wernitznig et al.
METALLOMICS (2019)
Functionalization and cancer-targeting design of ruthenium complexes for precise cancer therapy
Jinggong Liu et al.
CHEMICAL COMMUNICATIONS (2019)
Anticancer Ruthenium(III) Complexes and Ru(III)-Containing Nanoformulations: An Update on the Mechanism of Action and Biological Activity
Claudia Riccardi et al.
PHARMACEUTICALS (2019)
Bax, Bak and beyond - mitochondrial performance in apoptosis
Aida Pena-Blanco et al.
FEBS JOURNAL (2018)
Dressing up an Old Drug: An Aminoacyl Lipid for the Functionalization of Ru(III)-Based Anticancer Agents
Claudia Riccardi et al.
ACS BIOMATERIALS SCIENCE & ENGINEERING (2018)
Dressing up an Old Drug: An Aminoacyl Lipid for the Functionalization of Ru(III)-Based Anticancer Agents
Claudia Riccardi et al.
ACS BIOMATERIALS SCIENCE & ENGINEERING (2018)
Lipid and Nucleic Acid Chemistries: Combining the Best of Both Worlds to Construct Advanced Biomaterials
Julie Baillet et al.
ADVANCED MATERIALS (2018)
Restoring the switch for cancer cell death: Targeting the apoptosis signaling pathway
Clement Chung
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2018)
Triple negative breast cancer: new therapeutic approaches and BRCA status
Gamze Guney Eskiler et al.
APMIS (2018)
Autophagy inducers in cancer
Maria Russo et al.
BIOCHEMICAL PHARMACOLOGY (2018)
Chemotherapeutic agents for the treatment of metastatic breast cancer: An update
Mariam Abotaleb et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Autophagy in health and disease: A comprehensive review
Sarbari Saha et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development
Samuel M. Meier-Menches et al.
CHEMICAL SOCIETY REVIEWS (2018)
Detailed account on activation mechanisms of ruthenium coordination complexes and their role as antineoplastic agents
Mousumi Pal et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Tamoxifen a pioneering drug: An update on the therapeutic potential of tamoxifen derivatives
Shagufta et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Exploring the conformational behaviour and aggregation properties of lipid-conjugated AS1411 aptamers
Claudia Riccardi et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2018)
Role of autophagy in breast cancer and breast cancer stem cells (Review)
Yanyan Han et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2018)
Ru(II) Compounds: Next-Generation Anticancer Metallotherapeutics?
Sreekanth Thota et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Crosstalk Between Apoptosis and Autophagy Is Regulated by the Arginylated BiP/Beclin-1/p62 Complex
Xinxin Song et al.
MOLECULAR CANCER RESEARCH (2018)
Arm against return of breast cancer
Balkees Abderrahman et al.
NATURE (2018)
Luminal A Breast Cancer and Molecular Assays: A Review
Jennifer J. Gao et al.
ONCOLOGIST (2018)
Recent Advances in the Treatment of Breast Cancer
Christy W. S. Tong et al.
FRONTIERS IN ONCOLOGY (2018)
A contemporary review of male breast cancer: current evidence and unanswered questions
Roberto A. Leon-Ferre et al.
CANCER AND METASTASIS REVIEWS (2018)
Autophagy as a Potential Therapeutic Target in Breast Cancer Treatment
Natalia Lisiak et al.
CURRENT CANCER DRUG TARGETS (2018)
Apoptosis propagates through the cytoplasm as trigger waves
Xianrui Cheng et al.
SCIENCE (2018)
Emerging ways to treat breast cancer: will promises be met?
Pouria Samadi et al.
CELLULAR ONCOLOGY (2018)
Environmental Carcinogenesis and Transgenerational Transmission of Carcinogenic Risk: From Genetics to Epigenetics
Ernesto Burgio et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2018)
The Roles of Autophagy in Cancer
Chul Won Yun et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Applications of Ruthenium Complex in Tumor Diagnosis and Therapy
Ke Lin et al.
FRONTIERS IN PHARMACOLOGY (2018)
Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer
Teresa Kaserer et al.
CELL CHEMICAL BIOLOGY (2018)
The BCL-2 arbiters of apoptosis and their growing role as cancer targets
Jerry M. Adams et al.
CELL DEATH AND DIFFERENTIATION (2018)
Neoadjuvant chemotherapy regimens in treatment of breast cancer: a systematic review and network meta-analysis protocol
Mona Pathak et al.
SYSTEMATIC REVIEWS (2018)
Thirty Years of the Drug Candidate NAMI-A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective
Enzo Alessio
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY (2017)
RuIII Complexes for Anticancer Therapy: The Importance of Being Nucleolipidic
Claudia Riccardi et al.
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2017)
A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin
Cynthia Licona et al.
ONCOTARGET (2017)
Exploiting cancer vulnerabilities: mTOR, autophagy, and homeostatic imbalance
Charlotte E. Johnson et al.
SIGNALLING MECHANISMS IN AUTOPHAGY (2017)
Recent Advances in Comprehending the Signaling Pathways Involved in the Progression of Breast Cancer
Andrea Nicolini et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Recent developments in the nanostructured materials functionalized with ruthenium complexes for targeted drug delivery to tumors
Prakash Thangavel et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2017)
Design, synthesis and evaluation of anticancer activity of ruthenium (II) polypyridyl complexes
Bing Tang et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2017)
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
David Cameron et al.
LANCET (2017)
Autophagy: The spotlight for cellular stress responses
Palaniyandi Ravanan et al.
LIFE SCIENCES (2017)
Triple negative breast cancer: the kiss of death
Adriana-Andreea Jitariu et al.
ONCOTARGET (2017)
Antiproliferative effects of ruthenium-based nucleolipidic nanoaggregates in human models of breast cancer in vitro: insights into their mode of action
Carlo Irace et al.
SCIENTIFIC REPORTS (2017)
Non-coding RNAs as a new dawn in tumor diagnosis
Anna Grimaldi et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2017)
Chemotherapy treatment induces an increase of autophagy in the luminal breast cancer cell MCF7, but not in the triple-negative MDA-MB231
Christian Garbar et al.
SCIENTIFIC REPORTS (2017)
Multi-Targeted Anticancer Agents
Wei Zheng et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2017)
The development of anticancer ruthenium(II) complexes: from single molecule compounds to nanomaterials
Leli Zeng et al.
CHEMICAL SOCIETY REVIEWS (2017)
Breast Cancer Molecular Stratification From Intrinsic Subtypes to Integrative Clusters
Hege G. Russnes et al.
AMERICAN JOURNAL OF PATHOLOGY (2017)
Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis
Beatrix Schoenhacker-Alte et al.
CANCER LETTERS (2017)
Breast cancer in young women: an overview
Zoi Anastasiadi et al.
UPDATES IN SURGERY (2017)
Targeting autophagy in cancer
Jean M. Mulcahy Levy et al.
NATURE REVIEWS CANCER (2017)
Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy
Juan Jin et al.
CANCER BIOLOGY & THERAPY (2017)
Assessment of Breast Cancer Risk Factors Reveals Subtype Heterogeneity
Johanna Holm et al.
CANCER RESEARCH (2017)
DNA repair and damage pathways in breast cancer development and therapy
Maryam Majidinia et al.
DNA REPAIR (2017)
Ruthenium complexes with phenylterpyridine derivatives target cell membrane and trigger death receptors-mediated apoptosis in cancer cells
Zhiqin Deng et al.
BIOMATERIALS (2017)
Supramolecular Delivery Systems for NonPlatinum Metal-Based Anticancer Drugs
Paola Ringhieri et al.
CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS (2017)
G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms
Paula J. Bates et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2017)
Epigenetic control of gene expression: Potential implications for cancer treatment
F. Perri et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Endogenous DNA Damage as a Source of Genomic Instability in Cancer
Anthony Tubbs et al.
CELL (2017)
Fighting Cancer with Transition Metal Complexes: From Naked DNA to Protein and Chromatin Targeting Strategies
Giulia Palermo et al.
CHEMMEDCHEM (2016)
HER-2 Positive Breast Cancer - a Mini-Review
Hafiz Muhammad Asif et al.
Asian Pacific Journal of Cancer Prevention (2016)
A BH3 Mimetic for Killing Cancer Cells
Douglas R. Green
CELL (2016)
Insights into the invitro Anticancer Effects of Diruthenium-1
Aneta Koceva-Chyla et al.
CHEMMEDCHEM (2016)
The development of RAPTA compounds for the treatment of tumors
Benjamin S. Murray et al.
COORDINATION CHEMISTRY REVIEWS (2016)
Therapeutic potential and critical analysis of trastuzumab and bevacizumab in combination with different chemotherapeutic agents against metastatic breast/colorectal cancer affecting various endpoints
Mohd Wahid et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Molecular mode of action of NKP-1339-a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines
Lea S. Flocke et al.
INVESTIGATIONAL NEW DRUGS (2016)
Cell-in-Cell Death Is Not Restricted by Caspase-3 Deficiency in MCF-7 Cells
Shan Wang et al.
JOURNAL OF BREAST CANCER (2016)
Biodistribution of the novel anticancer drug sodium trans-Retrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action
Anna K. Bytzek et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2016)
Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy
Mohammad Abid et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2016)
Luminal B breast cancer: patterns of recurrence and clinical outcome
Zhi-hua Li et al.
ONCOTARGET (2016)
Inhibition of ERα/ERK/P62 cascades induces autophagic switch in the estrogen receptor-positive breast cancer cells exposed to gemcitabine
Peng Shen et al.
ONCOTARGET (2016)
Tamoxifen synergizes with 4-(E)-{(4-hydroxyphenylimino)-methylbenzene, 1,2-diol} and 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, novel azaresveratrol analogs, in inhibiting the proliferation of breast cancer cells
Amruta Ronghe et al.
ONCOTARGET (2016)
Lipooligosaccharides as Amphiphiles to Build Liposomes for Effective Drug Delivery: The Case of Anticancer Ruthenium Complex-Based Aggregates
Federica Acampora et al.
CHEMISTRYSELECT (2016)
A Network-Based Data Integration Approach to Support Drug Repurposing and Multi-Target Therapies in Triple Negative Breast Cancer
Francesca Vitali et al.
PLOS ONE (2016)
Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies
Alex R. D. Delbridge et al.
NATURE REVIEWS CANCER (2016)
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in- human, open-label, dose-escalation phase I study with expansion cohort
Howard A. Burris et al.
ESMO OPEN (2016)
Tumoral heterogeneity of breast cancer
Aurelie Roulot et al.
ANNALES DE BIOLOGIE CLINIQUE (2016)
Differences in clinical importance of Bcl-2 in breast cancer according to hormone receptors status or adjuvant endocrine therapy
Naoko Honma et al.
BMC CANCER (2015)
The BCL-2 protein family, BH3-mimetics and cancer therapy
A. R. D. Delbridge et al.
CELL DEATH AND DIFFERENTIATION (2015)
Autophagy, Metabolism, and Cancer
Eileen White et al.
CLINICAL CANCER RESEARCH (2015)
Interaction of anticancer Ru(III) complexes with single stranded and duplex DNA model systems
Domenica Musumeci et al.
DALTON TRANSACTIONS (2015)
Caspase-mediated crosstalk between autophagy and apoptosis: Mutual adjustment or matter of dominance
Rani Ojha et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2015)
Ruthenium complex Lambda-WH0402 induces hepatocellular carcinoma LM6 (HCCLM6) cell death by triggering the Beclin-1-dependent autophagy pathway
Jian Yuan et al.
METALLOMICS (2015)
Target profiling of an antimetastatic RAPTA agent by chemical proteomics: relevance to the mode of action
Maria V. Babak et al.
CHEMICAL SCIENCE (2015)
Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?
Michelle M. Williams et al.
ONCOTARGET (2015)
Cationic liposomes as efficient nanocarriers for the drug delivery of an anticancer cholesterol-based ruthenium complex
Giuseppe Vitiello et al.
JOURNAL OF MATERIALS CHEMISTRY B (2015)
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
Suzanne Leijen et al.
INVESTIGATIONAL NEW DRUGS (2015)
PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling
S. E. Moody et al.
ONCOGENE (2015)
The role of cell signalling in the crosstalk between autophagy and apoptosis
Laurence A. Booth et al.
CELLULAR SIGNALLING (2014)
The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells
Ming Chen et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2014)
NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
Robert Trondl et al.
CHEMICAL SCIENCE (2014)
Synthesis and Evaluation of Novel Pyrroles and Pyrrolopyrimidines as Anti-Hyperglycemic Agents
M. S. Mohamed et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Anticancer Cationic Ruthenium Nanovectors: From Rational Molecular Design to Cellular Uptake and Bioactivity
Gaetano Mangiapia et al.
BIOMACROMOLECULES (2013)
Rationally Designed Multitarget Anticancer Agents
Zhuo Chen et al.
CURRENT MEDICINAL CHEMISTRY (2013)
A new design for nucleolipid-based Ru(III) complexes as anticancer agents
Daniela Montesarchio et al.
DALTON TRANSACTIONS (2013)
Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies
Orsolya Doemoetoer et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2013)
Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (-) and ER (+) Breast Cancer
Ibrahim Tekedereli et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2013)
Cholesterol-Based Nucleolipid-Ruthenium Complex Stabilized by Lipid Aggregates for Antineoplastic Therapy
Luca Simeone et al.
BIOCONJUGATE CHEMISTRY (2012)
Ruthenium-based complex nanocarriers for cancer therapy
Gaetano Mangiapia et al.
BIOMATERIALS (2012)
Pyridine Analogues of the Antimetastatic Ru(III) Complex NAMI-A Targeting Non-Covalent Interactions with Albumin
Michael I. Webb et al.
INORGANIC CHEMISTRY (2012)
Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices
Vanessa Allain et al.
NUCLEIC ACIDS RESEARCH (2012)
Platinum-Based Compounds for the Treatment of Metastatic Breast Cancer
Ali I. Shamseddine et al.
CHEMOTHERAPY (2011)
Breast Development and Anatomy
Sonali Pandya et al.
CLINICAL OBSTETRICS AND GYNECOLOGY (2011)
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs
Alberta Bergamo et al.
DALTON TRANSACTIONS (2011)
Nucleolipid nanovectors as molecular carriers for potential applications in drug delivery
Luca Simeone et al.
MOLECULAR BIOSYSTEMS (2011)
Choosing the right cell line for breast cancer research
Deborah L. Holliday et al.
BREAST CANCER RESEARCH (2011)
Metal complexes in medicine with a focus on enzyme inhibition
Chi-Ming Che et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339
Petra Heffeter et al.
JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY (2010)
Lipid based nanovectors containing ruthenium complexes: a potential route in cancer therapy
Mauro Vaccaro et al.
CHEMICAL COMMUNICATIONS (2009)
KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
Christian G. Hartinger et al.
CHEMISTRY & BIODIVERSITY (2008)
Emerging Protein Targets for Anticancer Metallodrugs: Inhibition of Thioredoxin Reductase and Cathepsin B by Antitumor Ruthenium (II)-Arene Compounds
Angela Casini et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms
Carsten A. Vock et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Drug penetration in solid tumours
Andrew I. Minchinton et al.
NATURE REVIEWS CANCER (2006)
From bench to bedside -: preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)
Christian G. Hartinger et al.
JOURNAL OF INORGANIC BIOCHEMISTRY (2006)
Nucleolipids: Natural occurrence, synthesis, molecular recognition, and supramolecular assemblies as potential precursors of life and bioorganic materials
H Rosemeyer
CHEMISTRY & BIODIVERSITY (2005)
A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent
JM Rademaker-Lakhai et al.
CLINICAL CANCER RESEARCH (2004)
Ruthenium antimetastatic agents
E Alessio et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2004)
A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A
M Bouma et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2002)
Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A
G Sava et al.
EUROPEAN JOURNAL OF CANCER (2002)
分享论文
